

Financial news for KBIO dated on 2017-06-26: KaloBios Pharma Uplisted to OTCQB from Pink

Financial news for KBIO dated on 2016-08-31: KaloBios Pharmaceuticals Issues Corporate Overview Presentation

Financial news for KBIO dated on 2016-08-29: Martin Shkreli Dissolves Stake in Kalobios Pharmaceuticals as of August 25, 2016

Financial news for KBIO dated on 2016-08-16: Kalabios Pharmaceuticals Files for Non-Timely 10Q

Financial news for KBIO dated on 2016-08-16: Dhar Kapil Reports 6.37% Passive Stake in KaloBios Pharmaceuticals in 13G

Financial news for KBIO dated on 2016-07-13: Norris Bay Reports 24.95% Stake in Kalabios in 13D

Financial news for KBIO dated on 2016-03-31: Kalobios Pharma Files Non-Timely 10-K

Financial news for KBIO dated on 2016-03-04: 8-K from KaloBios Shows Co. Named Chair Dr. Cameron Durrant as CEO

Financial news for KBIO dated on 2016-02-04: Turing Pharmaceuticals Says to Their Knowledge, No Patient Needs to Pay \$750/Pill for Daraprim -Reuters

Financial news for KBIO dated on 2016-02-02: UPDATE: KaloBios Says 'Deeply Disappointed' by US Trustee's 'Unfortunate,' 'Unnecessary' Action to File Motion

Financial news for KBIO dated on 2016-02-02: KaloBios Pharma Offers Statement Related to US Trustee Motion

Financial news for KBIO dated on 2016-01-22: Hearing Letter from Martin Shkreli's Lawyer Shows He Would 'Gladly Cooperate' If Congress Immunized Testimony

Financial news for KBIO dated on 2016-01-12: KaloBios Pharmaceuticals, Inc. Withdraws Appeal on Nasdaq Delisting

Financial news for KBIO dated on 2016-01-12: 8-K from KaloBios Shows Election of Ronald Barliant as Chair, Cameron Durrant as Chair of Board's Audit, Compensation Committees

Financial news for KBIO dated on 2016-01-12: Nasdaq To Suspend KaloBios Pharmaceuticals Shares From Exchange As Of Jan. 13th 2016

Financial news for KBIO dated on 2016-01-11: KaloBios Pharmaceutical Reports Ronald Barliant and Dr. Cameron Durrant Elected As Independent Directors To The Board. Dr. Durrant Named Chairman Of Board

Financial news for KBIO dated on 2016-01-07: Martin Shkreli Puts Up \$45 Million E*Trade Account To Cover \$5 Million Bailout

Financial news for KBIO dated on 2016-01-07: Hearing Martin Shkreli Has Put His \$45M E*TRADE Account Up for Bail Security

Financial news for KBIO dated on 2016-01-06: Form D Filing from KaloBios Pharma Shows Co. Sold ~\$8.218M in Equity Financing

Financial news for KBIO dated on 2015-12-31: Tim Sykes: Lucas Energy A 'Potential Short' Amid Low Volume Run-Up

Financial news for KBIO dated on 2015-12-31: NASDAQ: KaloBios' Bankruptcy Announcement Constitutes A 'Separate And Additional Basis' For Stock

Financial news for KBIO dated on 2015-12-31: KaloBios Pharma Release Shows Co. Notified by NASDAQ of Added Bases for Delisting

Financial news for KBIO dated on 2015-12-31: 3 CEOs Who Made Headlines In 2015

Financial news for KBIO dated on 2015-12-30: 8-K from KaloBios Shows Confirmation of Voluntary Petition for Bankruptcy Protection Under Ch. 11

Financial news for KBIO dated on 2015-12-30: KaloBios Files For Bankruptcy

Financial news for KBIO dated on 2015-12-30: US Stock Futures Drop Ahead Of Pending Home Sales Report

Financial news for KBIO dated on 2015-12-30: Kalobios Pharmaceuticals Files for Chapter 11 Bankruptcy

Financial news for KBIO dated on 2015-12-29: Kalobios Submits Documents To Appeal Nasdaq Delisting, Hearing Scheduled For Feb 25, 2016

Financial news for KBIO dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for KBIO dated on 2015-12-28: 8-K from KaloBios Pharma Shows Co. Directors Tom Fernandez, Marek Biestek Resigned from Board on Dec. 27, '15

Financial news for KBIO dated on 2015-12-24: KaloBios To Trade On 'Grey Markets'

Financial news for KBIO dated on 2015-12-23: OTC Markets Spokesperson Says Kalobios Likely to Trade on 'Grey Market' and Not One of the OTC Markets, Since it has been Halted

Financial news for KBIO dated on 2015-12-23: KaloBios Pharmaceuticals Press Release Confirms That It Was Notified by Nasdaq Stock Market of Delisting

Financial news for KBIO dated on 2015-12-23: 8-K from KaloBios Shows Interim CFO Christopher Thorn Submitted Resignation

Financial news for KBIO dated on 2015-12-23: Kalobios Shares May be Suspended from Trading on Nasdaq at Opening of Business on December 30, 2015

Financial news for KBIO dated on 2015-12-21: Martin Shkreli Tells Wall Street Journal Drug Price Hikes, Over-The-Top Persona Reasons Behind His Arrest

Financial news for KBIO dated on 2015-12-21: Martin Shkreli @MartinShkreli Tweet: I was hacked--I now have control of this account. -- @MartinShkreli

Financial news for KBIO dated on 2015-12-21: The Shkreli Top? History Could Be Repeating Itself

Financial news for KBIO dated on 2015-12-21: KaloBios Pharmaceuticals, Inc. Releases PR Confirming Martin Shkreli Terminated As CEO and Resigns As Board Member, Tony Chase Also Resigns As Member Of Board

Financial news for KBIO dated on 2015-12-20: University of California at Davis, Moffitt Cancer Center in Florida, Suspend Planned KaloBios Pharmaceuticals-Sponsored Drug Trial Following arrest of CEO Martin Shkreli -Bloomberg

Financial news for KBIO dated on 2015-12-18: Director Harrison Buys 1,705 Shares Of Kalobios Pharmaceuticals @\$29.32/Share -Form 4

Financial news for KBIO dated on 2015-12-18: Turing Pharma Says Daraprim Remains Available, Distribution Uninterrupted, All Patients In Need Will Have Access

Financial news for KBIO dated on 2015-12-18: Turing Pharmaceuticals Announces CEO Martin Shkreli To Resign, Ron Tilles Interim CEO-Meg Tirell CNBC

Financial news for KBIO dated on 2015-12-18: 13G Shows KaloBios Holder PrimeCap Liquidates Stake From Last Report Of 12.97% Shares Outs. On Sept 30

Financial news for KBIO dated on 2015-12-18: Adam Feuerstein @adamfeuerstein Tweet: Turing Pharma investor confirms for me ongoing effort underway by Series A investors to remove Martin Shkreli as CEO.

Financial news for KBIO dated on 2015-12-18: UPDATE: DJ Reports Martin Shkreli to Step Down as Turing CEO; No Word on Permanent or Interim CEO Replacement

Financial news for KBIO dated on 2015-12-18: Nasdaq Says No Update on Resumption of Kalobios Trading; Shares have been Halted Since 6:48 AM ET on Thursday

Financial news for KBIO dated on 2015-12-18: Turing Pharmaceuticals Close to Replacing Martin Shkreli as CEO

Financial news for KBIO dated on 2015-12-17: Martin Shkreli-KaloBios Saga An Example Of How Penny Stocks Can Be Misunderstood, Tim Sykes Says

Financial news for KBIO dated on 2015-12-17: After-Hours Reuters Article 'Imprimis, a Turing rival, aims to undercut drug price hikes' Includes Interview with Co. CEO Mark Baum

Financial news for KBIO dated on 2015-12-17: Martin Shkreli Released on \$5M Bond, Travel Restricted to Eastern, Southern Districts of NY -CNBC

Financial news for KBIO dated on 2015-12-17: UPDATE: Retrophin Says Has 'added new members to Board mgmt team, implemented new financial controls, further developed its

pipeline of promising drugs for patients with rare diseases...'

Financial news for KBIO dated on 2015-12-17: UPDATE: Retrophin Says 'Under current leadership, [co.] continues to move forward'

Financial news for KBIO dated on 2015-12-17: UPDATE: Retrophin Says Has Authorized Independent Investigation, Filed Suit Against Shkreli, Co. Fully Cooperating with Gov't Probe

Financial news for KBIO dated on 2015-12-17: Retrophin Issues Statement on Shkreli's Indictment

Financial news for KBIO dated on 2015-12-17: Tim Sykes Tells Benzinga He Is Looking To "Aggressively" Short Shares Of KaloBios, Now That The Martin Has Been Arrested; Thinks It Could Fall 90% Over Next Few Weeks

Financial news for KBIO dated on 2015-12-17: Tim Sykes Tells Benzinga KaloBios Was A 'Smokescreen', A Supernova That Defied Logic, Have to Be Skeptical In Surge Of Company Not Based On Earnings Or New Product Released

Financial news for KBIO dated on 2015-12-17: Spokesperson for Savant HWP Tells Benzinga They Have No Idea at this Time if the Sale of Benznidazole Program for the Treatment of Chagas Disease to Kalobios Will be Completed

Financial news for KBIO dated on 2015-12-17: Hearing Prosecutor Has Said Investigation Into Martin Shkreli's Alleged Schemes 'Ongoing'

Financial news for KBIO dated on 2015-12-17: CNBC's Meg Tirrell Tweets: 'Breaking: Shkreli to be arraigned 2pm today in Brooklyn'

Financial news for KBIO dated on 2015-12-17: Nasdaq Halts KaloBios Pharmaceuticals, NASDAQ Says Trading Will Remain Halted Until They Satisfy Request For Additional Information

Financial news for KBIO dated on 2015-12-17: Nasdaq has No Further Information on Kalobios Halt; No Information on When it Will Resume Trading

Financial news for KBIO dated on 2015-12-17: UPDATE: Indictment To Also charge Evan Greebel, Outside Counsel Of Retrophin-U.S. Prosecutors

Financial news for KBIO dated on 2015-12-17: Turing Pharmaceuticals Says Both New York and Switzerland Offices Open for Business Today; No Immediate Comment on Martin Shkreli Arrest

Financial news for KBIO dated on 2015-12-17: Hearing Martin Shkreli Will Be Named Indictment in Federal Court in Brooklyn, NY Related To Retrophin-U.S. Prosecutors

Financial news for KBIO dated on 2015-12-17: Benzinga's Top #PreMarket Losers

Financial news for KBIO dated on 2015-12-17: Early Global News: Obama Meets Bloomberg, Microsoft Supplying Chinese Government With Windows 10, And More

Financial news for KBIO dated on 2015-12-17: KaloBios Plummets 50% After Martin Shkreli Is Arrested For Fraud

Financial news for KBIO dated on 2015-12-17: Kalobios Halted, Information Request By Nasdaq

Financial news for KBIO dated on 2015-12-17: KaloBios Pharmaceuticals Fall 49% Premarket to \$12.00 Following Report of Arrest of CEO Martin Shkreli

Financial news for KBIO dated on 2015-12-17: Shares of KaloBios Down ~49% After Bloomberg Reports Martin Shkreli Arrested for Fraud

Financial news for KBIO dated on 2015-12-14: KaloBios' Next Support Level Could Be 15% Lower Than Current Prices

Financial news for KBIO dated on 2015-12-12: Early Global News: Final Draft Of Global Climate Change Deal, China's Retail Sales Up, Bridgestone To Acquire Pep Boys

Financial news for KBIO dated on 2015-12-11: Don't Manage Trades Like Joe Campbell

Financial news for KBIO dated on 2015-12-09: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-12-07: New York Times Bio On Martin Shkreli Weighs On KaloBios Pharma Stock

Financial news for KBIO dated on 2015-12-07: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-12-07: Kalobios Pharmaceuticals +10% Premarket Following Positive Newsletter Mention

Financial news for KBIO dated on 2015-12-07: Little Bear Research Says Kalobios Valued at \$135/Share Within 18 Months

Financial news for KBIO dated on 2015-12-04: KaloBio peaks In \$34 handle for third day in a row (highs between \$34.30-\$34.63). Watch minor support at \$30, and major support at Thursday's low \$28.02

Financial news for KBIO dated on 2015-12-04: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-12-04: KaloBios Pharmaceuticals +29.60% Premarket; On Thursday, Co Announced Agreement to Acquire Benznidazole Program for the Treatment of Chagas Disease, Plus Private Placement @\$29.27/Share

Financial news for KBIO dated on 2015-12-03: UPDATE: KaloBios Pharmaceuticals in Talks to Acquire Additional Assets in Next 30-90 Days

Financial news for KBIO dated on 2015-12-03: Shares of KaloBios Spiked to High of \$39.86 in After Hours, Up ~37% from Close; Gains Pared to \$36.75, Shares Still Up ~25%

Financial news for KBIO dated on 2015-12-03: UPDATE: KaloBios to Receive Gross Proceeds of ~\$8.2M in Exchange for Issuance to Investors of 280,170 Shares of Common Stock of Company

Financial news for KBIO dated on 2015-12-03: KaloBios Reports Raising of \$8.2M Private Placement

Financial news for KBIO dated on 2015-12-03: UPDATE: KaloBios Says Upon Approval of Orphan, Fast Track Drug Designation for Benznidazole, Expects to Receive Neglected Tropical Disease Priority Review Voucher

Financial news for KBIO dated on 2015-12-03: UPDATE: KaloBios Says Planning to File for Orphan, Fast Track Drug Designation for Benznidazole in Chagas Disease

Financial news for KBIO dated on 2015-12-03: KaloBios Announces Agreement to Acquire Benznidazole Program for the Treatment of Chagas Disease, Upfront Payment \$2M Plus Regulatory Payments

Financial news for KBIO dated on 2015-11-30: Volume Drying Up In KaloBios After Last Week's Surge

Financial news for KBIO dated on 2015-11-30: KaloBios Pharmaceuticals Spikes to High of \$36.88

Financial news for KBIO dated on 2015-11-30: KaloBios Pharmaceuticals Spikes Higher

Financial news for KBIO dated on 2015-11-30: Morning Market Losers

Financial news for KBIO dated on 2015-11-30: Benzinga's Top #PreMarket Losers

Financial news for KBIO dated on 2015-11-30: UPDATE: KaloBios Pharmaceuticals Reverse Course, Now +\$0.17 Premarket @\$35.00

Financial news for KBIO dated on 2015-11-30: KaloBios Pharmaceuticals -31% Premarket

Financial news for KBIO dated on 2015-11-29: Benzinga's Weekend M&A Chatter

Financial news for KBIO dated on 2015-11-27: Hearing Unconfirmed Takeover Chatter Cyclacel Could be Takeover Target for Martin Shkreli and Kalobios

Financial news for KBIO dated on 2015-11-27: Shkreli Short-Squeeze In KaloBios Executed To Perfection?

Financial news for KBIO dated on 2015-11-27: Why Is Martin Shkreli No Longer Lending Out His KaloBios Shares?

Financial news for KBIO dated on 2015-11-27: Benzinga's Volume Movers

Financial news for KBIO dated on 2015-11-27: Morning Market Gainers

Financial news for KBIO dated on 2015-11-27: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-11-27: Kalobios +69% Premarket @\$45.00

Financial news for KBIO dated on 2015-11-25: KaloBios Attempts To Consolidate After Four Volatile Sessions

Financial news for KBIO dated on 2015-11-25: Shkreli Says He's 'Not A One Trick Pony'

Financial news for KBIO dated on 2015-11-25: Shkreli Says 'I Think R&D is By Far the Greatest Return in BioPharma'

Financial news for KBIO dated on 2015-11-25: Martin Shkreli Sees "No Reason Or Need" To Reverse Merger Turing And KaloBios; In Talks For 3 Separate Acquisitions In Rare Diseases, 1 FDA Approved Drug and 2 Not Yet Approved Drugs

Financial news for KBIO dated on 2015-11-25: Shkreli Says 'Its Not Some Stock Market Game or a Trick,' Its About Getting Patients a Drug They Need

Financial news for KBIO dated on 2015-11-25: Shkreli Says He Doesn't Pay Attention to the Stock Market

Financial news for KBIO dated on 2015-11-25: When Asked If Shkreli is Doing Any Trading in KaloBios, Highlights SEC Filing Required Within 48 Hours, 'So You'll Know'

Financial news for KBIO dated on 2015-11-25: Martin Shkreli Bought Shares of KaloBios In Open Market, Was Not Able To Reach Management Team

Financial news for KBIO dated on 2015-11-25: Shkreli Says The Best Way Patients Can Keep Out-of-Pocket-Costs Low: 'Insurance'

Financial news for KBIO dated on 2015-11-25: Shkreli Says, "Hospitals will get the discounts" They Are Focusing on Top 800 Hospitals

Financial news for KBIO dated on 2015-11-25: Martin Shkreli on Bloomberg Says, "[Daraprim] has always been affordable to every customer who needs it"

Financial news for KBIO dated on 2015-11-25: Martin Shkreli Appearing on BBG TV

Financial news for KBIO dated on 2015-11-25: Shares of KaloBios Recently Bouncing Off \$26 Level Ahead of Martin Shkreli Interview on Bloomberg; Stock Up ~52% to \$27.92 at Last Check

Financial news for KBIO dated on 2015-11-25: UPDATE: 13D from Shkreli on KaloBios Shows Aggregate Share Count of 2.89M

Financial news for KBIO dated on 2015-11-25: KaloBios Shares Trading Higher Off Of Shkreli 13D Filing, Trading AT \$26.77/Share

Financial news for KBIO dated on 2015-11-25: 13D Filing from Martin Shkreli on KaloBios Shows 70.1% Stake

Financial news for KBIO dated on 2015-11-25: Martin Shkreli: Who's Tim Sykes?

Financial news for KBIO dated on 2015-11-25: Benzinga's Volume Movers

Financial news for KBIO dated on 2015-11-25: Morning Market Gainers

Financial news for KBIO dated on 2015-11-25: Kalobios Spikes Higher at the Open to \$26.50

Financial news for KBIO dated on 2015-11-25: Martin Shkreli @MartinShkreli Tweet: Going to be on Bloomberg TV today at 1pm--hopefully this time the President doesn't interrupt. Talking \$KBIO

Financial news for KBIO dated on 2015-11-25: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-11-24: Tuesday's After-Hours Movers: HP, Hewlett Packard Enterprise, 21Vianet, Guess? And KaloBios

Financial news for KBIO dated on 2015-11-24: Martin Shkreli @MartinShkreli Tweet: TV schedule got warped so will probably do it tomorrow.

Financial news for KBIO dated on 2015-11-24: KaloBios Pharma Shares Selloff More Than \$6 Quickly, Trades Through \$28.50 Technical Level, \$24.50 Next Support Level

Financial news for KBIO dated on 2015-11-24: Kalobios Shares Sell Off to Low; Appears Martin Shkreli's Bloomberg Spot Bumped Due to Obama-Hollande Press Conference

Financial news for KBIO dated on 2015-11-24: Tim Sykes Says Expects Kalobios to Return to Penny Stock -NY Post

Financial news for KBIO dated on 2015-11-24: Shares of KaloBios Plunge Over Last Few Mins as \$36 Level Given Up; Stock Now Down ~15% to \$33.60

Financial news for KBIO dated on 2015-11-23: Martin Shkreli @MartinShkreli Tweet: Turnaround in progress. \$KBIO pic.twitter.com/5dseMG3B8I

Financial news for KBIO dated on 2015-11-23: Shares Of Kalobios Spiking After Trade Halt

Financial news for KBIO dated on 2015-11-23: Kalobios Resumes Trading Following Halt #2; Falls to \$36

Financial news for KBIO dated on 2015-11-23: KalBios Pharma Shares Resume Trading, Shares Below HOD, Currently Trading \$38.00

Financial news for KBIO dated on 2015-11-23: KaloBio Pharma Shares Halted On Volatility

Financial news for KBIO dated on 2015-11-23: Kalobios Resumes Trading; Falls Below \$40

Financial news for KBIO dated on 2015-11-23: Kalobios Halted on Circuit-Breaker +150%

Financial news for KBIO dated on 2015-11-23: UPDATE: Kalobios Breaks Above \$40; +124%

Financial news for KBIO dated on 2015-11-23: Kalobios Pharma Shares Push To HOD \$38, Currently Trading \$37.14

Financial news for KBIO dated on 2015-11-23: Kalobios +68%; Breaks Above \$30

Financial news for KBIO dated on 2015-11-23: Benzinga's Volume Movers

Financial news for KBIO dated on 2015-11-23: Stocks Hitting 52-Week Highs

Financial news for KBIO dated on 2015-11-23: Morning Market Gainers

Financial news for KBIO dated on 2015-11-23: Kalobios Pharam Break Above \$23, Up ~26%

Financial news for KBIO dated on 2015-11-23: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-11-23: Kalobios +12% Premarket @\$20.50

Financial news for KBIO dated on 2015-11-20: 10 Stocks Moving In Friday's After-Hours Session

Financial news for KBIO dated on 2015-11-20: A Look At A Trading Nightmare

Financial news for KBIO dated on 2015-11-20: Shkreli Works His Magic In KaloBios

Financial news for KBIO dated on 2015-11-20: Benzinga's Volume Movers

Financial news for KBIO dated on 2015-11-20: Stocks Hitting 52-Week Highs

Financial news for KBIO dated on 2015-11-20: UPDATE: Shares of KaloBios Now Up ~86% to \$19.35

Financial news for KBIO dated on 2015-11-20: Shares of KaloBios Resume Trade, Now Up 122%

Financial news for KBIO dated on 2015-11-20: Shares of KaloBios Halted Up 102%; Stock Set to Resume in ~1 Min

Financial news for KBIO dated on 2015-11-20: Morning Market Gainers

Financial news for KBIO dated on 2015-11-20: Early Global News: Mali Radisson Attack, Depomed-Horizon Fallout, EU Cracking Down On Bitcoin

Financial news for KBIO dated on 2015-11-20: KaloBios Names Controversial Martin Shkreli As Its New CEO

Financial news for KBIO dated on 2015-11-20: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-11-20: KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing

Financial news for KBIO dated on 2015-11-19: KaloBios Ends Wild Day Up 400%; Down Slightly After-Hours

Financial news for KBIO dated on 2015-11-19: KaloBios Shares Spiking Sharply Over Last 40 Mins: Broke Above \$11 Level to Consolidation Phase Around \$12, Now Up Another \$0.43

Financial news for KBIO dated on 2015-11-19: What To Do When A Penny Stock Goes Crazy: Lessons From KaloBios

Financial news for KBIO dated on 2015-11-19: Marek Biestek Buys 40,000 Share of Kalobios Pharmaceuticals @\$2.04/Share -Form 4

Financial news for KBIO dated on 2015-11-19: Martin Shkreli Buys 440,000 Shares of Kalobios Pharmaceuticals @\$2.02/Share -Form 4

Financial news for KBIO dated on 2015-11-19: Marek Biestek Buys 200,000 Shares Of Kalobios Pharmaceuticals @\$1.68/Share -Form 4

Financial news for KBIO dated on 2015-11-19: Benzinga's Volume Movers

Financial news for KBIO dated on 2015-11-19: Morning Market Gainers

Financial news for KBIO dated on 2015-11-19: Benzinga's Top #PreMarket Gainers

Financial news for KBIO dated on 2015-11-19: KaloBios, The Aftermath: Trader Starts GoFundMe To Pay Back \$106,000 Balance

Financial news for KBIO dated on 2015-11-19: UPDATE: KaloBios Shares Hit Pre-Market High at \$24.55, Now Down to ~\$18.03

Financial news for KBIO dated on 2015-11-19: UPDATE: KaloBios Shares +1000% Premaket @\$23.49 on Report of Shkreli Stake

Financial news for KBIO dated on 2015-11-19: KaloBios Pharmaceuticals +750% Pre-Market @\$17.53 Following Report of Shkreli, Anthion Partners Stakes

Financial news for KBIO dated on 2015-11-18: KaloBios Confirms Communications with Majority Shareholder Group Comprised of Martin Shkreli and Associate

Financial news for KBIO dated on 2015-11-18: Martin Shkreli Makes 1,080% On Penny Stock Days After Company Said It Would Shut Down

Financial news for KBIO dated on 2015-11-18: UPDATE: KaloBios Shares Now Up ~625% to \$15.01 At Last Check, Touched High of \$15.77

Financial news for KBIO dated on 2015-11-18: Turing Pharma CEO Form-4 Purchase Equals ~29.37% Of Kalobios Pharma Shares Outstanding

Financial news for KBIO dated on 2015-11-18: KaloBios Shares Trading Up 330% Following Huge ~1.2M Share Purchase by Martin Shkreli

Financial news for KBIO dated on 2015-11-18: Short Interest in KaloBios Pharmaceuticals 9.36% as of October 30, 2015; Shares Traded at \$66.00 in January 2013

Financial news for KBIO dated on 2015-11-18: Martin Shkreli Buys 1,211,115 Of Kalobios Pharmaceuticals @\$1.35/Share -Form 4

Financial news for KBIO dated on 2015-11-13: KaloBios Reports Will Wind Down Operations, Has Engaged Brenner Group to Lead Wind-Down Efforts

Financial news for KBIO dated on 2015-11-13: KaleBios Pharma Shares Halted News Pending

Financial news for KBIO dated on 2015-11-06: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2015-11-06: Morning Market Losers

Financial news for KBIO dated on 2015-11-05: Shares of KaleBios to Resume Trade at 6 p.m. EST

Financial news for KBIO dated on 2015-11-05: Shares of KaleBios to Resume Trade at 6 p.m. EST

Financial news for KBIO dated on 2015-11-05: KaloBios to Reduce Workforce By 17 Employees, Explore Strategic Alternatives

Financial news for KBIO dated on 2015-11-05: Kalebios Shares Halted News Pending

Financial news for KBIO dated on 2015-11-05: Kalebios Shares Halted News Pending

Financial news for KBIO dated on 2015-09-11: Kalobios Pharma Spikes Higher on Volume

Financial news for KBIO dated on 2015-09-08: Morning Market Losers

Financial news for KBIO dated on 2015-09-08: Benzinga's Top #PreMarket Losers

Financial news for KBIO dated on 2015-08-10: KalBios Pharma Reports Q2 Loss \$1.46 Vs est Loss \$1.68

Financial news for KBIO dated on 2015-07-29: KaloBios Reports FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia

Financial news for KBIO dated on 2015-07-13: KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split

Financial news for KBIO dated on 2015-05-11: KaloBios Reports Q1 EPS \$(0.29) vs. Est. \$(0.30)

Financial news for KBIO dated on 2015-03-04: John Welsh @johnwelshtrades Tweet: \$KBIO 100% guarantee of a raise today or tomorrow. That's what they said on the last CC, they will do it into this volume.

Financial news for KBIO dated on 2015-02-27: Kalobios Pharma Shares Spike Hiher

Financial news for KBIO dated on 2015-02-02: Kalobios To Cut 20% of Jobs

Financial news for KBIO dated on 2015-01-08: KaloBios CEO Pritchard To Retire; Herb Cross As Interim CEO

Financial news for KBIO dated on 2015-01-07: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2015-01-07: Morning Market Losers

Financial news for KBIO dated on 2015-01-07: Wednesday Morning Movers

Financial news for KBIO dated on 2015-01-07: Benzinga's Top #PreMarket Losers

Financial news for KBIO dated on 2015-01-06: Tuesday's After-Hours Movers

Financial news for KBIO dated on 2015-01-06: Shares of KaloBios Resume Trade, Now Down ~56%

Financial news for KBIO dated on 2015-01-06: KaloBios Pharma Shares to Resume Trade at 4:30 p.m. EST

Financial news for KBIO dated on 2015-01-06: UPDATE: KaloBios Reports Top-Line Data

Financial news for KBIO dated on 2015-01-06: KaloBios Offers Top-Line Data from Phase 2 Study of KB001-A; Study Does Not Meet Primary Endpoint

Financial news for KBIO dated on 2015-01-06: KaloBios Pharma Shares Halted News Pending

Financial news for KBIO dated on 2014-08-07: Kalobios Pharmaceuticals Reports Q2 EPS of \$(0.30) vs \$(0.34) Est

Financial news for KBIO dated on 2014-07-29: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2014-07-28: Shares of KaloBios Pharma Trading Down ~12%

Financial news for KBIO dated on 2014-07-28: KaloBios Pharma Shares to Resume Trade at 4:30 p.m. EDT

Financial news for KBIO dated on 2014-07-28: KaloBios Pharmaceuticals Expects to Release Top-Line Data on Phase 2 Study in Early Q1 of 2015

Financial news for KBIO dated on 2014-07-28: KaloBios Will Regains All Rights to KaloBio's KB001-A Progarm From Sanofi

Financial news for KBIO dated on 2014-07-28: KaloBios Pharma Halted News Pending

Financial news for KBIO dated on 2014-05-08: Kalobios Pharmaceuticals Reports Q1 EPS of \$(0.32) vs \$(0.38) Est

Financial news for KBIO dated on 2014-05-06: Ted W. Love, M.D., Named Chairman of the Board of KaloBios

Financial news for KBIO dated on 2014-03-13: Kalobios Pharmaceuticals Reports FY EPS of \$(1.73) vs \$(1.71) Est

Financial news for KBIO dated on 2014-02-27: JMP Securities Initiates Coverage on Kalobios Pharmaceuticals at Market Outperform, Announces \$8.00 PT

Financial news for KBIO dated on 2014-02-11: KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies

Financial news for KBIO dated on 2014-01-30: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2014-01-30: Needham Downgrades Kalobios Pharmaceuticals to Hold

Financial news for KBIO dated on 2014-01-30: Benzinga's Top #PreMarket Losers

Financial news for KBIO dated on 2014-01-29: KaloBios Shares Down Over 44% Following Poor Phase 2 Study Results From KB003

Financial news for KBIO dated on 2014-01-29: KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma; Failed to Meet Primary Endpoint

Financial news for KBIO dated on 2014-01-29: KaloBios Therapeutics Halted News Pending

Financial news for KBIO dated on 2013-11-12: Kalobios Pharmaceuticals Reports Q3 EPS of \$(0.47) vs \$(0.48) Est; Revenue of \$9.0K

Financial news for KBIO dated on 2013-11-04: Hungry For Some Action Ahead Of Twitter's Open? Here Are Some Of The Best And Worst IPOs Of 2013...

Financial news for KBIO dated on 2013-10-29: KaloBios Pharmaceuticals Gets FDA Orphan Designation for PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody

Financial news for KBIO dated on 2013-10-23: KaloBios Elects Laurie Smaldone Alsup, M.D. to Board

Financial news for KBIO dated on 2013-09-23: KaloBios Pharmaceuticals Announces Offering of Common Stock

Financial news for KBIO dated on 2013-09-19: Herb C. Cross to Join KaloBios as Chief Financial Officer

Financial news for KBIO dated on 2013-09-03: Kalobios Pharma Files \$100M Mixed Securities Shelf

Financial news for KBIO dated on 2013-08-05: KaloBios Announces Retirement Of Chief Financial Officer

Financial news for KBIO dated on 2013-06-17: KaloBios Appoints Donald R. Joseph as Chief Legal Officer

Financial news for KBIO dated on 2013-06-06: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2013-04-15: Top Performing Industries For April 15, 2013

Financial news for KBIO dated on 2013-03-05: Kalobios Pharma Shares Outperforming as Needham Initiates at Buy, \$11 Target

Financial news for KBIO dated on 2013-02-26: William Blair Initiates Coverage on Kalobios Pharmaceuticals at Outperform

Financial news for KBIO dated on 2013-02-26: Leerink Swann Initiates Coverage on Kalobios Pharmaceuticals at Outperform

Financial news for KBIO dated on 2013-02-13: Stocks Hitting 52-Week Lows

Financial news for KBIO dated on 2013-01-31: Kalobios Pharma IPO Opens for Trade Around \$8.10

Financial news for KBIO dated on 2013-01-31: Shares of KaloBios Pharma Now Open for Quote, Expected to Open for Trade at 11:40AM EST

Financial news for KBIO dated on 2013-01-30: Kalobios Pharma IPO Cuts IPO Price Range from \$12-14 Previously to \$8-9/Share